References in periodicals archive ?
"MPO and mdmX both recognize the survey as an opportunity to establish a common viewpoint that can be used by all companies in the industry for analysis, planning, and decision-making," said Sean Fenske, editor-in-chief for MPO.
"If the results cause company leaders to take a harder look at their markets, customers, pricing, and delivery, then the survey has done its job," added Tony Freeman, a strategic advisor to the precision manufacturing and specialty materials industries and executive director of mdmX.
In normal cells, p53 are carefully controlled at a low concentration by MDM2 and MDMX, presented MDM2 are required for development and protect cells from cellular stress .
Olivares-Illana, "Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB," Genes & Cancer, vol.
Qiu et al., "MDMX exerts its oncogenic activity via suppression of retinoblastoma protein," Oncogene, vol.
Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle.
Sin embargo, a pesar de los resultados obtenidos en el analisis, no fue posible encontrar diferencias significativas para r en el diametro mesiodistal ([H.sub.(1, N=16)]= 0,5404, p=0,4623) de los ocho dientes al comparar el maxilar (MDMx) con la mandibula (MDMn).
Repetibilidad (r), error estandar (es) de r, tamano muestral de la correlacion (N), varianza fenotipica ([V.sub.P]) y varianza ambiental especial ([V.sub.Es]) del diametro mesiodistal por pieza dentaria del maxilar (MDMx) y la mandibula (MDMn).
Jude team proved not only that the p53 pathway was activated in early retinoblastoma but also that excessive levels of a molecule called MDMX blocked it from triggering apoptosis in more advanced tumors.
H1 will also feature a new microarchitecture; a next-generation instruction set, MIPS V, that can pair two 32-bit operations in its 64-bit data path; and support for MIPS' Digital Media Extensions (MDMX).
Freeman also heads mdmX, an industry association for medical device contract manufacturers.
ALRN-6924 is designed to reactivate p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDM2 and MDMX. ALRN-6924 is being evaluated in Phase 1 and Phase 2 clinical trials in patients with AML, myelodysplastic syndrome and peripheral T-cell lymphoma.In AML, blood-forming stem cells in the bone marrow produce abnormal red and white blood cells as a result of damage to DNA.
Acronyms browser ?
Full browser ?